Brexpiprazole QW

Otsuka is running a Phase 3 trial of a once-weekly oral extended-release tablet formulation of brexpiprazole, the company's atypical antipsychotic sold as daily-oral Rexulti [1]. NCT05325645 tests the QW tablet against placebo in acute schizophrenia (n=450), with PANSS total score change as the primary endpoint and an estimated primary completion of March 2026 [1]. Important framing correction: this is NOT a long-acting injectable. The QW formulation is two 24 mg oral tablets dosed once weekly (24 mg initial titration, 48 mg maintenance), the same oral route as the existing daily Rexulti [1][5][6]. The strategic logic shifts accordingly: oral brexpiprazole's compound patent (US 8,470,813) expires June 25, 2032, and a once-weekly oral extends franchise life by reducing pill burden without forcing patients into the depot LAI paradigm [9]. The competitive landscape is also different than for an LAI - no once-weekly oral antipsychotic exists today, so the QW positions between daily orals (cheap, adherence-dependent) and depot LAIs (J&J paliperidone, aripiprazole depots, Teva Uzedy) rather than competing head-to-head with depots. The trial design is conventional and the mechanism is one of the most validated in psychiatry, so the efficacy question is unusually low-risk. The harder questions are PK (maintaining therapeutic plasma levels across a 7-day dosing interval) and commercial (whether 'weekly oral' is a real adherence improvement over daily oral).

This is a new oral formulation of an already-approved compound, not a new molecular entity. Brexpiprazole was approved by FDA in 2015 (NDA 205422) for schizophrenia and as adjunct to antidepressants in major depression [2], with a 2023 label expansion (sNDA - a supplemental NDA, the regulatory filing used to add new uses or formulations to an already-approved drug) on May 10, 2023, for agitation associated with dementia due to Alzheimer's disease, the first drug ever approved for that indication [3]. The QW formulation is an oral extended-release tablet (24 mg and 48 mg strengths), which materially de-risks the program because PK, safety, and the efficacy ceiling of the molecule are well-characterized from a decade of post-marketing experience [5][6]. NCT05325645 is currently recruiting 450 patients with acute schizophrenia, with estimated primary completion in March 2026 [1]. A companion long-term safety trial NCT05326347 (n=190) is active and no longer recruiting, with estimated completion September 2025, providing the chronic-exposure database needed for a supplemental NDA [4]. Two Phase 1 oral-dose studies characterized the pharmacokinetics: single/multiple dose PK (NCT04118127) and food effect (NCT06036108) [5][6]. The program goes Phase 1 → Phase 3 directly with no separate Phase 2 LAI/QW efficacy study disclosed - this is typical for reformulations where the efficacious plasma concentration window is already established from the approved daily-oral product. No FDA breakthrough, fast track, or orphan designations have been disclosed for the QW program. Otsuka has not published a target submission date.

Brexpiprazole is a serotonin-dopamine activity modulator. It partial-agonizes dopamine D2 receptors (think of D2 as the volume knob for psychotic symptoms: full blockade causes movement disorders like the old generation antipsychotics, partial agonism dials the signal down without flatlining it), antagonizes 5-HT2A (which improves negative symptoms such as social withdrawal and reduces movement side effects), and partial-agonizes 5-HT1A (which contributes to the anxiolytic and antidepressant effects that drove the MDD adjunct indication). Open Targets scores DRD2 at 0.745 for schizophrenia, putting it in the highest evidence tier for psychiatric targets. The mechanism is validated three times over: by aripiprazole, the structural sibling and prototype D2 partial agonist; by oral brexpiprazole's own pivotal trials; and by cariprazine, a third D2 partial agonist approved for schizophrenia and bipolar. The pharmacology question for this QW formulation is not whether brexpiprazole works in schizophrenia (it does) but whether weekly oral dosing maintains steady-state plasma levels comparable to daily oral without trough-related symptom breakthrough (the risk that drug levels dip too low at day 6-7 before the next dose, allowing positive symptoms to re-emerge) or peak-related side effects on dosing day. The Phase 1 program (NCT04118127 single/multiple-dose PK, NCT06036108 food effect) was designed to answer exactly this PK question, and both studies completed without disclosed safety or PK signals that halted progression [5][6].

NCT05325645 is a randomized placebo-controlled Phase 3 in acute schizophrenia, n=450, with change from baseline in PANSS (Positive and Negative Syndrome Scale, the standard schizophrenia rating instrument; 30 items, score 30-210, higher is worse) total score at the last visit of the double-blind period as the primary endpoint [1]. The intervention is oral brexpiprazole QW: a 24 mg initial titration dose followed by 48 mg maintenance (two 24 mg tablets) dosed once weekly [1][5]. Placebo comparator is the FDA-expected design for acute schizophrenia registration trials and matches the studies that supported oral brexpiprazole's 2015 approval [2]. The 450-patient size is adequate to detect a typical 4-6 point PANSS effect over placebo. The companion long-term safety study NCT05326347 (n=190, active not recruiting, est. completion September 2025) collects the chronic-exposure database the FDA requires for sustained dosing [4]. With primary completion estimated March 2026 [1] and a typical 6-week double-blind acute schizophrenia period, topline readout is most likely in mid-to-late 2026 (H2 2026), assuming no enrollment slippage. The main design risk is enrollment pace: acute schizophrenia trials globally have slowed since the pandemic, and Otsuka has not published interim recruitment updates. No head-to-head versus daily oral brexpiprazole or any antipsychotic LAI is planned, which keeps the regulatory path clean but means the commercial differentiation story (weekly vs daily oral) has to be built post-approval from real-world adherence data rather than from a randomized comparison.

Our model estimates an 11% chance this drug is eventually approved. That starting point comes from the historical approval rate for Phase 3 drugs in this area, which is about 46%. The estimate is pulled down mainly by heavier-than-usual blinding, few secondary endpoints, and weak earlier-phase results - though it is partly offset by the sponsor's strong track record of getting drugs approved. The remaining factors are close to average for this stage, so they don't move the number much.

The dominant risk here is commercial, not clinical, and the risk profile is meaningfully different from an LAI launch. Brexpiprazole oral generates substantial revenue for the Otsuka-Lundbeck partnership - Lundbeck reported FY2024 Rexulti sales of DKK 5.2 billion (~$822M, +16% YoY at constant currencies), which is only Lundbeck's portion; Otsuka holds primary US commercialization rights so the global franchise total is materially larger [7]. The competitive landscape: there is no once-weekly oral antipsychotic on the market today, so the QW formulation is differentiated. The depot LAI market (J&J paliperidone Invega Sustenna/Trinza/Hafyera, Otsuka's own aripiprazole Abilify Maintena/Asimtufii, Otsuka-partnered Aristada, Teva's Uzedy, risperidone Perseris/Consta) is a separate segment serving patients who need or accept injections - the QW oral instead targets patients who manage daily oral but would benefit from reduced pill burden, a distinct commercial position. Safety risks are well-characterized for brexpiprazole (akathisia, a distressing inner restlessness and urge to move that causes many patients to stop taking their medication; weight gain; sedation; metabolic effects) and the QW formulation inherits all of them with the added concern that elevated dosing-day peak concentrations could amplify acute side effects. Payer risk is real: brexpiprazole compound patent US 8,470,813 expires June 25, 2032, with formulation patents through October 12, 2032 and exclusivity through April 12, 2033 [9]; an ANDA was reportedly approved for Alembic in January 2025 [9] though market entry remains pending. A QW oral launching in 2027-2028 would have only ~4-5 years before daily-oral genericization erodes pricing power, and formulary negotiations against cheap generic aripiprazole, generic risperidone, and entrenched paliperidone depot contracts will be hard.

Worth watching, but for commercial signals more than efficacy ones. The PANSS readout from NCT05325645 is expected to separate from placebo cleanly given the molecule's track record; a failure would be the surprise. The signals that matter: (a) NCT05325645 status flipping from RECRUITING to ACTIVE_NOT_RECRUITING, which marks enrollment completion and lets you tighten the topline readout window (currently H2 2026 by our estimate from the March 2026 primary completion date) [1]; (b) Otsuka commentary on Rexulti franchise extension strategy in upcoming quarterly disclosures, particularly any guidance on QW submission timing - the next near-term catalyst is Otsuka Holdings (4578) Q1 FY2026 results (typically reported early August 2026) and Lundbeck's H1 2026 interim results (early August 2026); (c) the long-term safety trial NCT05326347 transitioning from ACTIVE_NOT_RECRUITING to COMPLETED (est. September 2025 - verify status) since that database is required for the sNDA [4]; (d) competitive moves from any oral antipsychotic franchise (Abbvie/Vraylar cariprazine, Sumitomo lurasidone) toward extended-release oral formulations that would erode the 'first weekly oral antipsychotic' positioning. The signal that would change the read most: if Otsuka announces a head-to-head trial versus daily oral brexpiprazole on adherence-derived endpoints, that says management believes the QW data is strong enough to claim differentiation. Re-check at next Otsuka quarterly or when NCT05325645 status updates.